HALO Halozyme Loading...

From INCY earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
Jul 28 ◎
Pablo CSO, Incyte Corporation INCY Q2 FY26 call
Collaborating with Halozyme to optimize the subcutaneous formulation of 9A9 using their enhanced delivery technology adds optionality and could improve patient experience for the drug.
HALO
HIGH

About HALO Analyst Coverage

Buzzberg tracks HALO (Halozyme) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Pablo.